| 0.6996 -0.059 (-7.74%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.9 |
1-year : | 0.96 |
| Resists | First : | 0.77 |
Second : | 0.82 |
| Pivot price | 0.75 |
|||
| Supports | First : | 0.68 | Second : | 0.57 |
| MAs | MA(5) : | 0.74 |
MA(20) : | 0.76 |
| MA(100) : | 0.73 |
MA(250) : | 0.86 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 39.7 |
D(3) : | 51.6 |
| RSI | RSI(14): 36.8 |
|||
| 52-week | High : | 2.06 | Low : | 0.32 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MGTA ] has closed below the lower bollinger band by 19.5%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 30.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.76 - 0.76 | 0.76 - 0.77 |
| Low: | 0.68 - 0.69 | 0.69 - 0.69 |
| Close: | 0.69 - 0.7 | 0.7 - 0.71 |
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Tue, 14 Nov 2023
FMR LLC Acquires New Stake in Magenta Therapeutics Inc - Yahoo Finance
Fri, 28 Jul 2023
Magenta Therapeutics: Potential Upside In The Merger, Wait To Buy More (MGTA) - Seeking Alpha
Wed, 03 May 2023
Magenta Therapeutics stock to merge with Dianthus in all-stock deal (NASDAQ:MGTA) - Seeking Alpha
Wed, 03 May 2023
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement - GlobeNewswire
Thu, 09 Feb 2023
Magenta's CEO Leaves After Patient Death Halts Trials, Shuttering Concerns Looms - Yahoo Finance
Fri, 03 Feb 2023
Magenta Therapeutics to shut down after patient death - Boston Business Journal - The Business Journals
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 62.6 (%) |
| Shares Short | 383 (K) |
| Shares Short P.Month | 393 (K) |
| EPS | -1.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.24 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.9 % |
| Return on Equity (ttm) | -65.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.95 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -73 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -0.61 |
| PEG Ratio | 0 |
| Price to Book value | 0.56 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|